Murali Divi

Murali Divi co-founded Divi's Laboratories in 1990 and continues to lead it as Managing Director. Based in Hyderabad, India, Divi's has grown into one of the world's leading manufacturers of active pharmaceutical ingredients (APIs), custom synthesis intermediates, and nutraceutical compounds. The company supplies APIs used in drugs across therapeutic areas including antiretrovirals, oncology, cardiovascular, and CNS — serving 95% of the world's top 25 pharmaceutical companies. Divi's operates two massive manufacturing campuses in Andhra Pradesh (near Visakhapatnam) with over 16 multi-purpose production units and extensive R&D capabilities. The company's competitive advantages include process chemistry expertise (developing more efficient synthesis routes for complex molecules), backward integration (producing key starting materials in-house), a strong regulatory track record (FDA, EMA, and other global regulatory approvals), and scale economies that enable competitive pricing. The company operates in two main segments: Generic APIs (manufacturing finished APIs that generic pharma companies formulate into final dosage forms) and Custom Synthesis (contract manufacturing of intermediates and APIs for innovator pharma companies — the higher-margin growth segment). Key stock drivers include API demand from global pharmaceutical companies, custom synthesis contract wins, pricing pressure in competitive generic APIs, regulatory inspection outcomes, capacity expansion, India's "China+1" positioning as an alternative API sourcing destination, and the pace of patent expirations creating new generic API opportunities.